{"entity":{"type":"insider","cik":"0001404598","url":"/insider/0001404598","json_url":"/insider/0001404598.json","name":"Platinum-Montaur Life Sciences, LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":24,"n_filings":7,"first":"2009-11-04","last":"2014-09-04","span_basis":"filed_date"},"name_variants":[{"name":"Platinum-Montaur Life Sciences, LLC","source":"filing","n_filings":7,"first_seen":"2009-11-04","last_seen":"2014-09-04"}],"transactions":[{"id":6487284,"accession":"0001140361-14-034864","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-14-034864","line_url":"/filing/0001140361-14-034864#line-1","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":null,"owner_name":"Platinum Partners Liquid Opportunity Master Fund L.P.; Platinum-Montaur Life Sciences, LLC; Platinum Liquid Opportunity Management (NY) LLC; Nordlicht Mark; LANDESMAN URI; Platinum Management (NY) LLC; Platinum Partners Value Arbitrage Fund, LP","owner_display_name":"Platinum Partners Liquid Opportunity Master Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock, par value $0.001","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":60000.0,"shares_display":"60,000","price_per_share":1.3592,"price_display":"1.36","price_state":"stated","total_value":81552.0,"total_display":"81,552.00","total_whole":"81,552","shares_owned_after":14946431.0,"shares_owned_after_display":"14,946,431","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-09-02","filed_date":"2014-09-04","scope":"insider"},{"id":6347232,"accession":"0001140361-14-027289","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-14-027289","line_url":"/filing/0001140361-14-027289#line-2","is_derivative":false,"issuer_cik":"0001031927","issuer_name":"Echo Therapeutics, Inc.","issuer_ticker":"ECTE","issuer_name_source":null,"issuer_url":"/issuer/0001031927","owner_cik":null,"owner_name":"Platinum Management (NY) LLC; Nordlicht Mark; Platinum Partners Value Arbitrage Fund, LP; Platinum Partners Liquid Opportunity Master Fund L.P.; Platinum-Montaur Life Sciences, LLC; Platinum Liquid Opportunity Management (NY) LLC; LANDESMAN URI","owner_display_name":"Platinum Management (NY) LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":55083.0,"shares_display":"55,083","price_per_share":2.2,"price_display":"2.20","price_state":"stated","total_value":121182.6,"total_display":"121,182.60","total_whole":"121,183","shares_owned_after":678452.0,"shares_owned_after_display":"678,452","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-06-30","filed_date":"2014-07-01","scope":"insider"},{"id":6347225,"accession":"0001140361-14-027289","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-14-027289","line_url":"/filing/0001140361-14-027289#line-1","is_derivative":false,"issuer_cik":"0001031927","issuer_name":"Echo Therapeutics, Inc.","issuer_ticker":"ECTE","issuer_name_source":null,"issuer_url":"/issuer/0001031927","owner_cik":null,"owner_name":"Platinum Management (NY) LLC; Nordlicht Mark; Platinum Partners Value Arbitrage Fund, LP; Platinum Partners Liquid Opportunity Master Fund L.P.; Platinum-Montaur Life Sciences, LLC; Platinum Liquid Opportunity Management (NY) LLC; LANDESMAN URI","owner_display_name":"Platinum Management (NY) LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10656.0,"shares_display":"10,656","price_per_share":2.2,"price_display":"2.20","price_state":"stated","total_value":23443.2,"total_display":"23,443.20","total_whole":"23,443","shares_owned_after":623369.0,"shares_owned_after_display":"623,369","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-06-27","filed_date":"2014-07-01","scope":"insider"},{"id":6347214,"accession":"0001140361-14-026909","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-14-026909","line_url":"/filing/0001140361-14-026909#line-2","is_derivative":false,"issuer_cik":"0001031927","issuer_name":"Echo Therapeutics, Inc.","issuer_ticker":"ECTE","issuer_name_source":null,"issuer_url":"/issuer/0001031927","owner_cik":null,"owner_name":"Platinum Management (NY) LLC; LANDESMAN URI; Platinum Liquid Opportunity Management (NY) LLC; Platinum Partners Liquid Opportunity Master Fund L.P.; Platinum-Montaur Life Sciences, LLC; Platinum Partners Value Arbitrage Fund, LP; Nordlicht Mark","owner_display_name":"Platinum Management (NY) LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":2.2,"price_display":"2.20","price_state":"stated","total_value":33000.0,"total_display":"33,000.00","total_whole":"33,000","shares_owned_after":612713.0,"shares_owned_after_display":"612,713","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-06-26","filed_date":"2014-06-27","scope":"insider"},{"id":6347207,"accession":"0001140361-14-026909","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-14-026909","line_url":"/filing/0001140361-14-026909#line-1","is_derivative":false,"issuer_cik":"0001031927","issuer_name":"Echo Therapeutics, Inc.","issuer_ticker":"ECTE","issuer_name_source":null,"issuer_url":"/issuer/0001031927","owner_cik":null,"owner_name":"Platinum Management (NY) LLC; LANDESMAN URI; Platinum Liquid Opportunity Management (NY) LLC; Platinum Partners Liquid Opportunity Master Fund L.P.; Platinum-Montaur Life Sciences, LLC; Platinum Partners Value Arbitrage Fund, LP; Nordlicht Mark","owner_display_name":"Platinum Management (NY) LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2300.0,"shares_display":"2,300","price_per_share":2.2,"price_display":"2.20","price_state":"stated","total_value":5060.0,"total_display":"5,060.00","total_whole":"5,060","shares_owned_after":597713.0,"shares_owned_after_display":"597,713","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-06-25","filed_date":"2014-06-27","scope":"insider"},{"id":6487017,"accession":"0001140361-14-026587","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-14-026587","line_url":"/filing/0001140361-14-026587#line-3","is_derivative":false,"issuer_cik":"0001031927","issuer_name":"Echo Therapeutics, Inc.","issuer_ticker":"ECTE","issuer_name_source":null,"issuer_url":"/issuer/0001031927","owner_cik":null,"owner_name":"Platinum Partners Liquid Opportunity Master Fund L.P.; Platinum-Montaur Life Sciences, LLC; Platinum Partners Value Arbitrage Fund, LP; Platinum Management (NY) LLC; Nordlicht Mark; LANDESMAN URI; Platinum Liquid Opportunity Management (NY) LLC","owner_display_name":"Platinum Partners Liquid Opportunity Master Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":386.0,"shares_display":"386","price_per_share":2.2,"price_display":"2.20","price_state":"stated","total_value":849.2,"total_display":"849.20","total_whole":"849","shares_owned_after":595413.0,"shares_owned_after_display":"595,413","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-06-24","filed_date":"2014-06-24","scope":"insider"},{"id":6487015,"accession":"0001140361-14-026587","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-14-026587","line_url":"/filing/0001140361-14-026587#line-2","is_derivative":false,"issuer_cik":"0001031927","issuer_name":"Echo Therapeutics, Inc.","issuer_ticker":"ECTE","issuer_name_source":null,"issuer_url":"/issuer/0001031927","owner_cik":null,"owner_name":"Platinum Partners Liquid Opportunity Master Fund L.P.; Platinum-Montaur Life Sciences, LLC; Platinum Partners Value Arbitrage Fund, LP; Platinum Management (NY) LLC; Nordlicht Mark; LANDESMAN URI; Platinum Liquid Opportunity Management (NY) LLC","owner_display_name":"Platinum Partners Liquid Opportunity Master Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":85.0,"shares_display":"85","price_per_share":2.2,"price_display":"2.20","price_state":"stated","total_value":187.0,"total_display":"187.00","total_whole":"187","shares_owned_after":595027.0,"shares_owned_after_display":"595,027","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-06-23","filed_date":"2014-06-24","scope":"insider"},{"id":6487013,"accession":"0001140361-14-026587","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-14-026587","line_url":"/filing/0001140361-14-026587#line-1","is_derivative":false,"issuer_cik":"0001031927","issuer_name":"Echo Therapeutics, Inc.","issuer_ticker":"ECTE","issuer_name_source":null,"issuer_url":"/issuer/0001031927","owner_cik":null,"owner_name":"Platinum Partners Liquid Opportunity Master Fund L.P.; Platinum-Montaur Life Sciences, LLC; Platinum Partners Value Arbitrage Fund, LP; Platinum Management (NY) LLC; Nordlicht Mark; LANDESMAN URI; Platinum Liquid Opportunity Management (NY) LLC","owner_display_name":"Platinum Partners Liquid Opportunity Master Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16490.0,"shares_display":"16,490","price_per_share":2.1996,"price_display":"2.20","price_state":"stated","total_value":36271.404,"total_display":"36,271.40","total_whole":"36,271","shares_owned_after":594942.0,"shares_owned_after_display":"594,942","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-06-20","filed_date":"2014-06-24","scope":"insider"},{"id":4530454,"accession":"0001140361-13-045902","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-13-045902","line_url":"/filing/0001140361-13-045902","is_derivative":false,"issuer_cik":"0001031927","issuer_name":"Echo Therapeutics, Inc.","issuer_ticker":"ECTE","issuer_name_source":null,"issuer_url":"/issuer/0001031927","owner_cik":null,"owner_name":"Platinum Liquid Opportunity Management (NY) LLC; Platinum Management (NY) LLC; Platinum Partners Liquid Opportunity Master Fund L.P.; Platinum Partners Value Arbitrage Fund, LP; Platinum Long Term Growth VII, LLC; LANDESMAN URI; Nordlicht Mark; Platinum-Montaur Life Sciences, LLC","owner_display_name":"Platinum Liquid Opportunity Management (NY) LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":69569.0,"shares_display":"69,569","price_per_share":2.75,"price_display":"2.75","price_state":"stated","total_value":191314.75,"total_display":"191,314.75","total_whole":"191,315","shares_owned_after":507824.0,"shares_owned_after_display":"507,824","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-12-10","filed_date":"2013-12-12","scope":"insider","n_lines":2},{"id":3550338,"accession":"0001140361-12-046566","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001140361-12-046566","line_url":"/filing/0001140361-12-046566#line-9","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":null,"owner_name":"Platinum Partners Value Arbitrage Fund, LP; Platinum-Montaur Life Sciences, LLC","owner_display_name":"Platinum Partners Value Arbitrage Fund, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.001","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":37030.0,"shares_display":"37,030","price_per_share":2.56,"price_display":"2.56","price_state":"stated","total_value":94796.8,"total_display":"94,796.80","total_whole":"94,797","shares_owned_after":6801016.0,"shares_owned_after_display":"6,801,016","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-10-10","filed_date":"2012-11-09","scope":"insider"},{"id":3550336,"accession":"0001140361-12-046566","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001140361-12-046566","line_url":"/filing/0001140361-12-046566#line-8","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":null,"owner_name":"Platinum Partners Value Arbitrage Fund, LP; Platinum-Montaur Life Sciences, LLC","owner_display_name":"Platinum Partners Value Arbitrage Fund, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.001","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4911.0,"shares_display":"4,911","price_per_share":3.24,"price_display":"3.24","price_state":"stated","total_value":15911.64,"total_display":"15,911.64","total_whole":"15,912","shares_owned_after":6763986.0,"shares_owned_after_display":"6,763,986","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-09-21","filed_date":"2012-11-09","scope":"insider"},{"id":3550334,"accession":"0001140361-12-046566","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001140361-12-046566","line_url":"/filing/0001140361-12-046566#line-7","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":null,"owner_name":"Platinum Partners Value Arbitrage Fund, LP; Platinum-Montaur Life Sciences, LLC","owner_display_name":"Platinum Partners Value Arbitrage Fund, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.001","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21700.0,"shares_display":"21,700","price_per_share":3.22,"price_display":"3.22","price_state":"stated","total_value":69874.0,"total_display":"69,874.00","total_whole":"69,874","shares_owned_after":6768897.0,"shares_owned_after_display":"6,768,897","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-09-19","filed_date":"2012-11-09","scope":"insider"},{"id":3550332,"accession":"0001140361-12-046566","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001140361-12-046566","line_url":"/filing/0001140361-12-046566","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":null,"owner_name":"Platinum Partners Value Arbitrage Fund, LP; Platinum-Montaur Life Sciences, LLC","owner_display_name":"Platinum Partners Value Arbitrage Fund, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.001","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":290419.0,"shares_display":"290,419","price_per_share":3.6942352600897324,"price_display":"3.69","price_state":"stated","total_value":1072876.11,"total_display":"1,072,876.11","total_whole":"1,072,876","shares_owned_after":6790597.0,"shares_owned_after_display":"6,790,597","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-09-10","filed_date":"2012-11-09","scope":"insider","n_lines":2},{"id":3550327,"accession":"0001140361-12-046566","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001140361-12-046566","line_url":"/filing/0001140361-12-046566#line-4","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":null,"owner_name":"Platinum Partners Value Arbitrage Fund, LP; Platinum-Montaur Life Sciences, LLC","owner_display_name":"Platinum Partners Value Arbitrage Fund, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.001","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":118731.0,"shares_display":"118,731","price_per_share":3.61,"price_display":"3.61","price_state":"stated","total_value":428618.91,"total_display":"428,618.91","total_whole":"428,619","shares_owned_after":7081016.0,"shares_owned_after_display":"7,081,016","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-09-07","filed_date":"2012-11-09","scope":"insider"},{"id":3550325,"accession":"0001140361-12-046566","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-12-046566","line_url":"/filing/0001140361-12-046566#line-3","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":null,"owner_name":"Platinum Partners Value Arbitrage Fund, LP; Platinum-Montaur Life Sciences, LLC","owner_display_name":"Platinum Partners Value Arbitrage Fund, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.001","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2200.0,"shares_display":"2,200","price_per_share":3.71,"price_display":"3.71","price_state":"stated","total_value":8162.0,"total_display":"8,162.00","total_whole":"8,162","shares_owned_after":7199747.0,"shares_owned_after_display":"7,199,747","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-09-06","filed_date":"2012-11-09","scope":"insider"},{"id":3550323,"accession":"0001140361-12-046566","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-12-046566","line_url":"/filing/0001140361-12-046566#line-2","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":null,"owner_name":"Platinum Partners Value Arbitrage Fund, LP; Platinum-Montaur Life Sciences, LLC","owner_display_name":"Platinum Partners Value Arbitrage Fund, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.001","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":64900.0,"shares_display":"64,900","price_per_share":3.78,"price_display":"3.78","price_state":"stated","total_value":245322.0,"total_display":"245,322.00","total_whole":"245,322","shares_owned_after":7201947.0,"shares_owned_after_display":"7,201,947","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-09-05","filed_date":"2012-11-09","scope":"insider"},{"id":3550321,"accession":"0001140361-12-046566","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-12-046566","line_url":"/filing/0001140361-12-046566#line-1","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":null,"owner_name":"Platinum Partners Value Arbitrage Fund, LP; Platinum-Montaur Life Sciences, LLC","owner_display_name":"Platinum Partners Value Arbitrage Fund, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.001","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":205521.0,"shares_display":"205,521","price_per_share":3.8,"price_display":"3.80","price_state":"stated","total_value":780979.8,"total_display":"780,979.80","total_whole":"780,980","shares_owned_after":7266847.0,"shares_owned_after_display":"7,266,847","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-09-04","filed_date":"2012-11-09","scope":"insider"},{"id":5738110,"accession":"0001140361-09-024643","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001140361-09-024643","line_url":"/filing/0001140361-09-024643#line-6","is_derivative":false,"issuer_cik":"0001125699","issuer_name":"DAIS ANALYTIC CORP","issuer_ticker":"DLYT.OB","issuer_name_source":null,"issuer_url":"/issuer/0001125699","owner_cik":null,"owner_name":"Nordlicht Mark; Platinum-Montaur Life Sciences, LLC","owner_display_name":"Nordlicht Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1153.0,"shares_display":"1,153","price_per_share":1.05,"price_display":"1.05","price_state":"stated","total_value":1210.65,"total_display":"1,210.65","total_whole":"1,211","shares_owned_after":3238204.0,"shares_owned_after_display":"3,238,204","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-09-25","filed_date":"2009-11-04","scope":"insider"},{"id":5738108,"accession":"0001140361-09-024643","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001140361-09-024643","line_url":"/filing/0001140361-09-024643#line-5","is_derivative":false,"issuer_cik":"0001125699","issuer_name":"DAIS ANALYTIC CORP","issuer_ticker":"DLYT.OB","issuer_name_source":null,"issuer_url":"/issuer/0001125699","owner_cik":null,"owner_name":"Nordlicht Mark; Platinum-Montaur Life Sciences, LLC","owner_display_name":"Nordlicht Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13550.0,"shares_display":"13,550","price_per_share":1.1,"price_display":"1.10","price_state":"stated","total_value":14905.0,"total_display":"14,905.00","total_whole":"14,905","shares_owned_after":3239357.0,"shares_owned_after_display":"3,239,357","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-09-24","filed_date":"2009-11-04","scope":"insider"},{"id":5738107,"accession":"0001140361-09-024643","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001140361-09-024643","line_url":"/filing/0001140361-09-024643#line-4","is_derivative":false,"issuer_cik":"0001125699","issuer_name":"DAIS ANALYTIC CORP","issuer_ticker":"DLYT.OB","issuer_name_source":null,"issuer_url":"/issuer/0001125699","owner_cik":null,"owner_name":"Nordlicht Mark; Platinum-Montaur Life Sciences, LLC","owner_display_name":"Nordlicht Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":61293.0,"shares_display":"61,293","price_per_share":1.73,"price_display":"1.73","price_state":"stated","total_value":106036.89,"total_display":"106,036.89","total_whole":"106,037","shares_owned_after":3252907.0,"shares_owned_after_display":"3,252,907","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-09-23","filed_date":"2009-11-04","scope":"insider"},{"id":5738104,"accession":"0001140361-09-024643","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-09-024643","line_url":"/filing/0001140361-09-024643#line-3","is_derivative":false,"issuer_cik":"0001125699","issuer_name":"DAIS ANALYTIC CORP","issuer_ticker":"DLYT.OB","issuer_name_source":null,"issuer_url":"/issuer/0001125699","owner_cik":null,"owner_name":"Nordlicht Mark; Platinum-Montaur Life Sciences, LLC","owner_display_name":"Nordlicht Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8500.0,"shares_display":"8,500","price_per_share":1.03,"price_display":"1.03","price_state":"stated","total_value":8755.0,"total_display":"8,755.00","total_whole":"8,755","shares_owned_after":3314200.0,"shares_owned_after_display":"3,314,200","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-09-22","filed_date":"2009-11-04","scope":"insider"},{"id":5738101,"accession":"0001140361-09-024643","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-09-024643","line_url":"/filing/0001140361-09-024643#line-2","is_derivative":false,"issuer_cik":"0001125699","issuer_name":"DAIS ANALYTIC CORP","issuer_ticker":"DLYT.OB","issuer_name_source":null,"issuer_url":"/issuer/0001125699","owner_cik":null,"owner_name":"Nordlicht Mark; Platinum-Montaur Life Sciences, LLC","owner_display_name":"Nordlicht Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2040.0,"shares_display":"2,040","price_per_share":1.0,"price_display":"1.00","price_state":"stated","total_value":2040.0,"total_display":"2,040.00","total_whole":"2,040","shares_owned_after":3322700.0,"shares_owned_after_display":"3,322,700","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-09-16","filed_date":"2009-11-04","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000810509","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","url":"/issuer/0000810509","role":"Ten percent owner","n_filings":2,"first_seen":"2012-11-09","last_seen":"2014-09-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001031927","name":"Echo Therapeutics, Inc.","url":"/issuer/0001031927","role":"Ten percent owner","n_filings":4,"first_seen":"2013-12-12","last_seen":"2014-07-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001125699","name":"DAIS ANALYTIC CORP","url":"/issuer/0001125699","role":"Ten percent owner","n_filings":1,"first_seen":"2009-11-04","last_seen":"2009-11-04"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001404598","retrieved_at":"2026-08-26T03:33:51+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}